COMP <GO>
AYTU vs UNH // ENTERPRISE SCALE & MARKET CAP
Aytu BioPharma Inc. (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: AYTU 0
— UNH 10
▲ ENTERPRISE SCALE & MARKET CAP LEADER: UNH
LAST: $1.94 (+0.52%) • MKT CAP: $21.1M
market-cap
$21.1M
LAST: $400.44 (-1.60%) • MKT CAP: $359.43B
market-cap
$359.43B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AYTU VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AYTU | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 88.31% | -19.31 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 12.38% | -47.38 | UNH | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -10.06% | 6.25% | -16.31 | UNH | /fcf-yield <GO> |
| Operating Margin | -11.80% | 5.32% | -17.12 | UNH | /operating-margins <GO> |
| Net Profit Margin | -20.50% | 3.53% | -24.03 | UNH | /net-margins <GO> |
| Revenue Growth (YoY) | 1.80% | 3.33% | -1.53 | UNH | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.29% | -2.29 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 3.09 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 7/9 | -2.00 | UNH | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | 7.00% | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 44.0 | 55.1 | -11.10 | UNH | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.33 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 17.7x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $21.1M | $359.43B | -$359.41B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AYTU REV | UNH REV | AYTU GROSS % | UNH GROSS % | AYTU FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $66.4M | $447.57B | 69.0% | 88.7% | -$2.2M | $16.07B |
| FY 2024 | $65.2M | $400.28B | 75.3% | 88.3% | -$1.7M | $20.70B |
| FY 2023 | $107.4M | $371.62B | — | 89.6% | -$5.1M | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AYTU // BETA —
UNH // BETA 0.33